3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Conditions
Carcinoma, Hepatocellular
7
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Liver Neoplasms
1
Liver Malignancy
1
Hepatic Malignancies
1
Carcinoma, Ovarian Epithelial
1
Bile Duct Neoplasms
1
Interventions
lutetium Lu 177 dotatate
34
Everolimus
33
lanreotide
13
gallium Ga 68 dotatate
13
Temozolomide
13
Magnetic Resonance Spectroscopy
13
Nivolumab
12
pembrolizumab
11
Octreotide
11
Capecitabine
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
surufatinib
8
Sunitinib
8
Specimen Handling
7
Carboplatin
7
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Lutetium-177
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Bevacizumab
5
telotristat ethyl
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neuroendocrine Tumors
×
Yttrium-90
×
Clear all
NCT04339036
2026-06-04
CapTemY90
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
70 enrolled
NCT04790708
2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA
Unknown
250 enrolled